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© 2011 ISHAM  Invasive aspergillosis is one of the most important infections in hematopoietic stem cell trans-
plant recipients, with an incidence rate of 5 – 15% and an associated mortality of 30 – 60%. It 
remains unclear why certain patients develop invasive aspergillosis while others, undergoing 
identical transplant regimen and similar post transplant immunosuppression, do not. Over the 
last decade, pattern recognition receptors such as Toll-like receptors (TLRs) and the C-type 
lectin receptors (CLRs) have emerged as critical components of the innate immune system. 
By detecting specifi c molecular patterns from invading microbes and initiating infl ammatory 
and subsequent adaptive immune responses, pattern recognition receptors are strategically 
located at the molecular interface of hosts and pathogens. Polymorphisms in pattern recogni-
tion receptors and downstream signaling molecules have been associated with increased or 
decreased susceptibility to infections, suggesting that their detection may have an increasing 
impact on the treatment and prevention of infectious diseases in the coming years. Infectious 
risk stratifi cation may be particularly relevant for patients with hematologic malignancies, 
because of the high prevalence and severity of infections in this population. This review sum-
marizes the innate immune mechanisms involved in  Aspergillus fumigatus detection and the 
role of host genetic polymorphisms in susceptibility to invasive aspergillosis. 
 Keywords  Aspergillus ,  innate immunity ,  genetic polymorphisms ,  toll-like receptors , 
 C-type lectins ,  allogeneic stem cell transplantation  Introduction 
 Invasive aspergillosis (IA) is an important cause of morbid-
ity and mortality in patients with hematological malignan-
cies and prolonged neutropenia. Its incidence depends on 
multiple factors (such as the type of underlying disease, 
oncological treatment, antimicrobial prophylaxis) and 
ranges from 5 – 15% in patients undergoing intensive 
myeloablative chemotherapy for acute leukemia or alloge-
neic hematopoietic stem cell transplantation (HSCT) [1 – 4]. 
Although the prognosis of IA has improved with the advent 
of new effective antifungal drugs, its mortality remains 
high (30 – 60%) [1,3 – 6]. d in fi nal revised form 9 July 2010; 
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 E-mail: Pierre-Yves.Bochud@chuv.ch  While early diagnosis is crucial, the non-specifi c clin-
ical presentation of IA together with the limited sensitiv-
ity of current diagnostic methods still makes it particularly 
challenging. Criteria of the European Organization for 
Research and Treatment of Cancer and Mycoses Study 
Group (EORTC-MSG) used to defi ne the probability 
of IA are often met late in the course of the disease [7]. 
The optimal management of IA among HSCT patients is 
under debate [8]. Various strategies have been proposed, 
including systematic antifungal prophylaxis [9,10], tar-
geted preemptive therapy (which is usually based on the 
use of circulating fungal antigens and radiological fi nd-
ings) [11,12] and empirical therapy [11,13]. The extended 
use of prophylactic agents has raised concerns about the 
emergence of resistance, changing epidemiology of 
molds, toxicity and costs [9,14]. Indeed, recent studies 
have highlighted the emergence of non- Aspergillus 
molds such as Zygomycetes which have reduced 
sensitivity to antifungal agents [6]. The sensitivity and DOI: 10.3109/13693786.2010.516408
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fi ndings, especially during the early course of infection, 
are suboptimal [15]. Recent developments in the fi eld of 
innate immunity and immunogenetics have opened new 
perspectives for the prevention and management of IA in 
patients with hematological malignancies. This review 
discusses the potential use of host genetic profi le for 
patient ’ s risk stratifi cation and individualized preventive 
strategies. 
 Innate immunity to Aspergillus fumigatus 
 A. fumigatus is a ubiquitous pathogen that can release large 
amounts of spores in the air. Due to their small size, conidia 
formed by asexual reproduction can be inhaled deep into 
the alveolar spaces [16]. In the immunocompetent host, the 
innate immune system is usually effi cient at clearing 
conidia before their germination into hyphae, the poten-
tially angioinvasive form of the pathogen. The respiratory 
epithelium represents a fi rst mechanical barrier (ciliated Nucleus
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Fig. 1 Pattern recognition receptors involved or potentially involved in the innate immune detection of  Aspergillus fumigatus . Microbial-associated 
molecular patterns (MAMPs) from the fungal cell wall are recognized by transmembrane or soluble pattern recognition receptors (PRRs), resulting in 
the activation of signal-transducing pathways and the production of cytokines and co-stimulatory molecules. MBL, mannose binding lectin; SP-A, 
surfactant protein A; SP-D, surfactant protein D; MyD88, myeloid differentiation primary response protein; TRIF, TIR-domain-containing adapter-
inducing interferon- β ; NOD2, nucleotide-binding oligomerization domain containing 2; RIP2, receptor interacting protein 2; CARD9, Caspase recruitment 
domain-containing protein 9; BCL10, B-cell lymphoma/leukemia 10; ROS, reactive oxygen species; NF- κ B, nuclear factor kappa B; IRF3, Interferon 
regulatory factor 3. © 2011 ISHAM, Medical Mycology, 49(Suppl. 1), S125–S136
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adaptor proteins to trigger signaling pathways, resulting 
in the activation of transcription factors (such as NF- κ B) 
and the production of cytokines and chemokines that are 
essential for the innate and subsequent adaptive immune 
responses. The number of known PRRs and their activa-
tors is expanding. Some PRRs such as the collectins 
(a subgroup of CLRs including mannose-binding lectin 
and surfactant proteins), complement factors or pentraxin 
3 are secreted molecules that act as opsonins [17]. At least 
two families of PRRs (TLRs and CLRs) have been 
in volved in the innate immune recognition of  Aspergillus 
fumigatus (Table 1). © 2011 ISHAM, Medical Mycology, 49(Suppl. 1), S125–S136
 In vitro/ex vivo experiments
PRRs
Macrophages 
(KO mice)
Involved Yes/No
Transfection
Involved 
Yes/No
Inhibition 1 
Involved 
Yes/No Toll-like receptors (TLRs) 
 The TLR family in mammals comprises 12 distinct trans-
membrane proteins, located on the cell surface (TLR1, 2, 
4, 5, 6) or within endocytic vesicles (TLR3, 7, 8, 9). The 
extracellular domain of TLRs is composed of leucin-rich 
repeat (LRRs) structures that are able to recognize a variety 
of MAMPs [18 – 20]. The interaction of TLRs with their 
specifi c MAMPs results in the activation of several adaptor 
proteins, such as the myeloid differentiation primary 
response protein 88 (MyD88) or the TIR-domain-contain-
ing adapter-inducing interferon- β (TRIF), that in turn initi-
ate the activation of transcription factors, such as the  Table 1 Role of Pattern Recognition Receptors (PRRs) and main signaling pathway in the innate immunity against  Aspergillus fumigatus infection 
(results of  in vivo/ex vivo/in vitr o studies).  In vivo experiments
Addition of 
soluble PRR
Involved Yes/No
Lethal model 
(KO mice)
Effect
Sublethal model 
(KO mice)
EffectToll-like receptors (TLRs)
TLR2 Yes [21 – 26]
No [28]
Yes [24 – 26] Yes [26,27] – – Absence is 
deleterious 2 [21,22]
No effect 2 [28]
TLR4 Yes [22,23,25,26] 3 
No [24,26,28] 3 
Yes [25]
No [24]
Yes [26,27] – – Absence is 
deleterious 2 [22]
No effect 2 [28]
TLR9 Yes [22,31] Yes [31] – – Absence is protective 
[22,32]
–
Other TLRs 
(1,3,5,6,7,8)
– No [25] – – – –
MyD88 Yes [22,24]
No [28,29]
Yes [85] – – – Absence is deleterious 
[22,30]
No effect [28]
C-type lectin receptors (CLRs)
Dectin-1 Yes [47,48] Yes [47] Yes [45 – 47] – – Absence is deleterious 
[47,48]
DC-SIGN – Yes [60] Yes [61] – – –
Mannose receptor 
(MR)
– – Yes [62] 4 – – –
Mannose binding 
lectins (MBL)
– – Yes [111] – Presence is protective 
[52,53]
–
Surfactant protein 
A (SP-A)
– – – Yes [52,54] No effect [52,56] –
Surfactant protein 
D (SP-D)
– – – Yes [52,54] Presence is protective 
[52,56]
–
NOD-like receptors (NLRs)
NLRP3 - - Yes [66] – – –
Others
Pentraxin-3 Yes [69] – Yes [69] – Presence is protective 
[70]
Absence is deleterious 
[69]
Complement 
(C5 component)
– – – – Presence is protective 
[74]
–
 1 This column regroups different possible modes of inhibition including silencing, antibodies, and purifi cation.  2 Effect on survival has been observed 
only in TLR2- and TLR4-defi cient immunocompromised mice (chemotherapy-induced neutropenia) [21,22], not in immunocompetent mice [22,28]. 
 3 Stimulation by  Aspergillus conidia only, not hyphae [22,23,26].  4 Murine dendritic cells. 
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1 (AP1) (Fig. 1). 
 All TLRs are expressed by respiratory epithelial cells 
and alveolar macrophages, and all TLRs but TLR3 are 
expressed by neutrophils [17]. Two TLRs (TLR2 and TLR4) 
and the MyD88 signaling pathway are involved in the innate 
immune detection of  A. fumigatus , as shown in  in vitro/ex 
vivo experiments, including cytokine expression in bone 
marrow macrophages form wild-type and TLR-defi cient 
mice [21 – 26], complementation of human cell lines with 
TLR plasmids [24 – 26] and gene silencing [26,27] (Table 
1). Some discrepant results regarding the role of TLR2 [28], 
TLR4 [24,26,28] and MyD88 [29] may be explained, at 
least in part, by changes in the MAMPs exposed to PRRs 
during the developmental stages of  A. fumigatus (resting, 
swollen, germinating conidia and hyphae). Similarly, neu-
tropenic mice defi cient in TLR2 and TLR4, as well as the 
mediator MyD88, were shown to have increased suscepti-
bility to IA in sublethal models of aspergillosis [21,22,30] 
(Table 1). However, no difference in survival has been 
observed among immunocompetent mice [22,28]. Some 
discrepancies may also result from the redundancy of the 
different PRRs involved in the pathogen recognition. TLR9, 
another MyD88 dependent-receptor, has also been involved 
in early detection of  A. fumigatus probably through its abil-
ity to bind the hypomethylated DNA present in the fungus 
[31]. While a mouse model of IA suggests a protective, 
albeit modest, effect [22,32], its role in modulating the 
cytokine response remains complex and poorly elucidated. 
To our knowledge, one single study using a cell comple-
mentation system investigated the role of other TLRs 
(TLR1, 3, 5, 6, 7, 8), which all seemed not to be involved 
in the innate immune detection of  A. fumigatus [25]. 
 The MAMPs from  A. fumigatus that activate TLR2 and 
TLR4 are unknown. However, chitin, a major polysaccha-
ride component of the fungal cell wall (present in all fungi 
including  Aspergillus spp.), has been shown to induce  in 
vitro cytokine production of murine macrophages and 
acute infl ammation in a mouse model through the activa-
tion of TLR2 [33]. Other MAMPs of the fungal cell wall 
have been identifi ed as TLRs activators in fungi other than 
 Aspergillus spp. (reviewed in [34]), including phospholi-
pomannans (TLR2) from  Candida albicans [35], mannans 
(TLR4) from  C. albicans and  Saccharomyces cerevisiae 
[36], glucuronoxylomannan (TLR4) from  Crypotococcus 
neoformans [37], beta-glucan (MyD88) from  Pneumocys-
tis carinii and  S. cerevisiae [38,39] and zymosan (TLR2, 
TLR6) from  S. cerevisiae [40]. 
 C-type lectin receptors (CLRs) 
 The large superfamily of CLRs is divided in 17 groups, 
characterized by the presence of at least one structurally related C-type lectin-like domain. Some CLRs, such as the 
transmembrane receptors Dectin-1 (group V) and Dectin-2 
(group II), the mannose receptor (MR, group VI), DC-SIGN 
(group II) and collectins (mannose-binding lectin [MBL] 
and lung surfactant proteins [SP], both group III) are 
involved in antifungal immunity (reviewed in [41]). 
 In the CLR family, the best characterized PRR is Dec-
tin-1, which is present on the surface of myeloid cells and 
is able to bind to the  β -glucan component of the fungal 
cell wall leading to the production of various cytokines 
and chemokines and the stimulation of phagocytosis 
[42,43]. Dectin-1 signaling pathway is mediated through 
the spleen tyrosine kinase (Syk) and the caspase recruit-
ment domain protein 9 (CARD9) [44]. The adjunctive 
role of some TLRs (TLR2 and 6) may however be required 
for certain functions [42]. Dectin-1 has been found to be 
highly expressed in alveolar macrophages and its role 
in the recognition of  A. fumigatus through the MAMP 
 β -glucan cell wall component and subsequent activation 
of the immune system has been shown by  in vitro and  in 
vivo analyses (Table 1) [45 – 48]. This mechanism of rec-
ognition is also dependent from the morphological 
changes of  A. fumigatus , being able to distinguish between 
dormant and potentially threatening spores, as the expo-
sure of  β -glucan on the cell wall occurs mainly during 
the swelling of conidia, which is the fi rst step of germina-
tion and transformation to invading hyphae [45 – 47]. 
Interestingly, Dectin-1 seems to be required for an effec-
tive response to  A. fumigatus in immunosuppressed as 
well as in immunocompetent mice [48], which is not 
the case for TLRs. Prophylactic administration of a fusion 
protein comprising the extracellular domain of Dectin-1 
has been tested in a neutropenic mouse model of IA with 
promising results [49].  Another transmembrane receptor of 
the CLRs family, Dectin-2, has been shown to trigger Th17 
response to fungal infection [50] and to elicit bone mar-
row-derived dentritic cells (BMDCs) response to  A. fumig-
atus [51]. 
 Collectins are soluble CLRs characterized by the 
presence of collagen. Their C-terminal region consists of 
a carbohydrate-recognition domain (CRD) which has the 
ability to interact with a wide range of microbial molecules 
and to activate the innate immune system [41]. Collectins 
such as the lung surfactant proteins (SP-A and SP-D) and 
the mannose-binding lectin (MBL) were shown to bind  in 
vitro to  A. fumigatus conidia in the presence of calcium 
acting as osponins for their phagocytosis by alveolar mac-
rophages and neutrophils [52]. The works of Madan  et al . 
have emphasized their role in the innate immune response 
against  A. fumigatus antigens or allergens and their thera-
peutic potential in murine models of invasive aspergillosis 
and allergic bronchopulmonary aspergillosis (Table 1) 
[52 – 59]. © 2011 ISHAM, Medical Mycology, 49(Suppl. 1), S125–S136
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 DC-SIGN is expressed exclusively on the surface of 
dendritic cells and a subset of macrophages through an 
IL-4 dependent manner and is able to recognize a wide 
spectrum of microbial agents [41]. DC-SIGN recognizes 
carbohydrates such as high-mannose structures. Some 
works have highlighted its ability to bind to  A. fumigatus 
conidia and mediate their internalization by dendritic cells 
and macrophages triggering their maturation (Table 1) 
[60,61]. It has been suggested that  A. fumigatus may use 
the DC-SIGN functions as a mean to escape immune rec-
ognition: increased DC-SIGN expression mediated by 
IL-4 may promote alternative activation of macrophages 
with reduced antifungal activity facilitating the develop-
ment of IA by persistence and germination of intracellular 
conidia [61]. 
 The mannose receptor (MR) is a transmembrane endo-
cytic receptor mainly expressed in macrophages and den-
dritic cells. Because of its ability to bind terminal mannose, 
fucose or N-acetyl glucosamine, MR is implicated in the 
recognition and immune response to various fungi such as 
 C. albicans ,  P. carinii and  C. neoformans [17,41]. One 
study suggests its role in the recognition and internaliza-
tion of A. fumigatus conidia by murine dendritic cells 
(Table 1) [62]. This function has not been confi rmed in 
human dendritic cells. A study using human Langerhans 
cells suggests their ability to recognize  A. fumigatus 
through a CLR with galactomannan specifi city distinct 
from mannose receptor [63]. 
 NOD-like receptors (NLRs) and RIG-I like receptors (RLRs) 
 NLRs (Nucleotide-binding domain, Leucin-Rich repeat 
containing) are conserved cytoplasmic proteins encoded by 
22 genes in humans that are involved in microbial recogni-
tion and responses to stress. Their action is mediated 
through the activation of multiprotein complexes (includ-
ing caspases) called infl ammasomes that trigger the matu-
ration of cytokines [64]. They can be subdivided in three 
subfamilies: NLRC (previously called NOD), NLRP and 
IPAF [64]. 
 Among NLRCs, NOD-2 is a receptor expressed essen-
tially by leukocytes, dendritic cells and epithelial cells 
which is well-known for its ability to bind to the peptido-
gylcan of gram-negative and gram-positive bacteria. Its 
role in the innate immune response to  A. fumigatus has 
been suggested by a recent study documenting  in vitro and 
 in vivo increased NOD-2 levels after stimulation by conidia, 
although direct evidence is lacking [65]. A study in human 
monocyte demonstrated that the NLRP3 infl ammasome is 
activated by  A. fumigatus hyphae leading to IL-1 β release 
[66]. NLRP3 signaling seems to rely on the Syk tyrosine 
kinase pathway, also activated by Dectin-1 and distinct 
from the MyD88 pathway of TLRs [66]. RLRs are cyto-plasmic RNA helicases, including RIG-I, MDA5 and 
LGP2, which are mainly involved in the recognition of 
viral RNA [67]. Their potential role in the innate immune 
response to fungal pathogens has not been established. 
 Other PRRs 
 In addition to these important families of PRRs, other sol-
uble molecules have been recognized as important media-
tors at the interface between host and pathogen. Some of 
them may be involved in the immune response to  A. fumig-
atus acting as opsonins and facilitating their elimination by 
the host ’ s immune system, such as pentraxins or proteins 
of the complement and the fi brinolytic pathways.  
 Pentraxins are conserved polymeric proteins repre-
senting a superfamily divided into two groups: short and 
long pentraxins. Pentraxin 3 (PTX3) is a long pentraxin 
produced by sentinel cells and released in response to 
cytokines in infl ammatory conditions that can bind to 
various microbial agents including A. fumigatus [68,69]. 
Lack of PTX3 is associated with defective recognition of 
 A. fumigatus conidia by alveolar macrophages and den-
dritic cells and with decreased survival in a murine model 
of invasive pulmonary aspergillosis (Table 1) [69]. The 
potential role of this soluble receptor in the treatment of 
invasive aspergillosis has also been studied with promising 
results suggesting a potentiating effect when combined 
with amphotericin B [70]. 
 Proteins of the complement have many antimicro-
bial properties including infl ammation, opsonization and 
pathogen destruction. The observation in 1989 that spores 
of  A. fumigatus were more susceptible to killing by alveo-
lar macrophages when serum has been heated to 56 ° C 
suggested a role of heat-labile serum components of the 
complement in antifungal defences [71]. Interactions of 
 A. fumigatus with the complement component C3 leading 
to the cleavage of C3 and the activation of an alternative 
pathway that facilitates phagocytosis, as well as the ability 
of the fungus to escape the activation of the complement, 
have been described [17,72,73]. An important role of 
the component C5 in the resistance to IA has also been 
suggested by a mouse model [74]. 
 As opposed to most PRRs, which were mainly discov-
ered by classical biological approaches, the identifi cation 
of plasminogen as an important contributor to the immune 
defences against  A. fumigatus resulted from a large genetic 
mapping study [75]. The role of plasminogen in the infl am-
matory response and mechanisms of microbial pathogenic-
ity such as invasion or dissemination has been widely 
described [76]. The demonstration that this protein may 
bind  in vitro to  A. fumigatus suggests its role in some 
mechanisms of pathogenicity of the fungus, such as hemor-
rhage and tissue damage associated with IA [75]. 
© 2011 ISHAM, Medical Mycology, 49(Suppl. 1), S125–S136
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sentinel cells are not PRRs, but the immunoregluatory 
effectors of the immune system and the ultimate product 
resulting from the interactions of MAMPs and PRRs. 
 Tumor Necrosis Factor alpha (TNF α ) stimulates vari-
ous functions of polymorphonuclear leukocytes including 
secretion of other cytokines, phagocytosis, oxidative respi-
ratory burst and degranulation. Its key role in the infl am-
matory response against  A. fumigatus has been demonstrated 
by  in vitro and  in vivo studies [77 – 79]. Various interleuk-
ines are secreted in response to  A. fumigatus . While some 
of them have a protective pro-infl ammatory role (IL-1, 
IL-6, IL-12 or IL-15), others seem to impede the host 
defences or to have controversial effects [17,80]. For 
instance, IL-10 suppresses the antifungal activity of mac-
rophages against  A. fumigatus , while increasing pha-
gocytosis [17,81]. A detrimental effect of the IL-23/IL-17 
pathway in the infl ammatory response and resistance 
against  A. fumigatus has recently been highlighted by  in 
vitro analyses and a murine model of invasive aspergillosis 
[82]. Chemokines, such as KC and MIP-2, have been 
shown to promote neutrophil recruitment in a murine 
model of IA [79,83,84]. MIP-2 is considered to be the 
murine homolog of IL-8 (not present in mice), a potent 
infl ammatory mediator which is secreted by human respi-
ratory cells and neutrophils in response to  A. fumigatus 
[23,85]. Chemokines receptors, such as CCR1, CCR6 and 
CXCR2, have also been shown to play a role in host 
defences against  A. fumigatus [86 – 88]. 
 Genetic polymorphisms of pattern 
recognition receptors and risk of aspergillosis 
 Invasive aspergillosis represents a particular interest for 
immunogenetic studies as it affects patients from a specifi c, 
relatively homogenous population (i.e., allogeneic hemato-
poietic stem cell transplant recipients) that can benefi t from 
preventive strategies. A relatively large number of studies 
have investigated the association of numerous SNPs or other 
genetic variations of different pattern recognition receptors 
(Table 2) or infl ammatory mediators (cytokines, chemok-
ines, Table 3) and an increased risk of aspergillosis. 
 Toll-like receptors (TLR) 
 A study identifi ed a donor haplotype in  TLR4 (containing 
the D299G and T399I SNPs) present at a frequency of 6% 
in the Caucasian population as a predictor of IA (22% vs 
5% at 6 months,  P   0.002) [89]. This association was 
confi rmed in a large (  300 patients) validation study. The 
presence of this TLR4 haplotype and/or of a CMV positive 
serostatus (donor or recipient) compared to negative results for both CMV and the TLR4 haplotype increased the 
3-year cumulative incidence of IA (12% vs 1%,  P   0.02) 
and death not related to relapse (35% vs 22%,  P   0.02). 
Although TLR4 has been shown to detect  A. fumigatus 
[22,23,25 – 27], the functional role of the D299G and T399I 
SNPs remains partially controversial [90]. The interaction 
of TLR4 with other pathogens such as CMV [91] or anti-
fungal drugs [92] has been proposed as alternative explana-
tions by which  TLR4 SNPs infl uence susceptibility to IA. 
However,  TLR4 D299G and T399I SNPs have been associ-
ated with susceptibility to aspergillosis in non-HSCT 
patients, who are not susceptible to CMV disease and usu-
ally did not receive antifungal agents prior to diagnosis 
[93]. Furthermore, CMV disease and  TLR4 SNPs seem to 
be independent factors for the risk of IA among HSCT 
recipients [89]. 
 Another study reported an association of the same 
SNP with fungal colonization in HSCT recipients, 
although this was not associated with an increased risk of 
IA in the small subset of colonized patients [94]. Discrep-
ancies between studies may be explained by several fac-
tors, such as different types of patients, differential 
assessment of demographic or clinical co-factors into 
multivariate models, and the power to detect associations. 
An increased risk of IA has also been associated with 
polymorphisms of TLR1 and TLR6 in HSCT recipients 
[95]. It is noteworthy that no genetic polymorphism pre-
disposing to aspergillosis has been identifi ed in TLR2 up 
to now, although it has been investigated in some studies 
[89,93,94]. However, the absence of genetic association 
should always be interpreted within the limited power of 
existing studies. 
 C-type lectin receptors (CLRs) 
 Some studies have investigated the role of polymorphisms 
in MBL and lung surfactant proteins in the development 
of aspergillosis (Table 2) [75,96 – 100]. Most of them 
addressed the issue of chronic pulmonary aspergillosis 
and not IA, comparing small series of cases with a control 
group. Although some of them suggest an association of 
the disease with some SNPs, the very limited sample size 
(  25 cases of aspergillosis) does not allow drawing fi rm 
conclusions. However, a role of the 868 C/T polymor-
phism in the MBL gene in predisposing to chronic pulmo-
nary aspergillosis is supported by two small studies 
showing concordant results [96,100]. The presence of 
SNPs in other CLRs that may affect the host ’ s response 
to  A. fumigatus has not been investigated up to now. 
The recent discovery of the association of an early stop 
polymorphism in dectin-1 with an increased susceptibility 
to colonization with  Candida species deserves further 
investigations with respect to IA [101]. 
© 2011 ISHAM, Medical Mycology, 49(Suppl. 1), S125–S136
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 Other PRRs 
 Using a genetic mapping model approach in a murine 
model, Zaas  et al . have identifi ed a SNP in the gene encod-
ing plasminogen that affected IA outcome in mice [75]. 
The association between this SNP and an increased sus-
ceptibility to IA was confi rmed in a large cohort study of 
HSCT recipients [75]. Such an interesting approach may 
allow the identifi cation of new PRRs and related polymor-
phisms improving our understanding of the pathogenesis 
of  A. fumigatus . 
 Cytokines and chemokines 
 Small association studies suggest that different SNPs in 
the genes encoding various cytokines and chemokines or 
their receptors may predispose to aspergillosis (Table 3) 
[102 – 109]. Concordant results suggesting an increased 
risk of aspergillosis related to the presence of a SNP in 
the encoding gene of interleukine 10 (G/A at position 
-1082) were described by two separate groups of investi-
gators [102,105]. These results deserve further investiga-
tions in larger data sets. 
 Synthesis and future perspectives 
 Over the last decade, PRRs appeared as major contributors 
of the immune responses to  A. fumigatus . Growing evi-
dence supports the role of TLR2, TLR4 and dectin-1 in 
the detection of the fungus. Furthermore, a number of 
studies investigated the association of polymorphisms in 
PRRs or cytokine genes with susceptibility to aspergillo-
sis. Certain polymorphisms are emerging as real risk fac-
tors, because the associations have been validated and/or 
functional consequences of the polymorphism have been 
clearly demonstrated. These data suggest that genetic 
markers may be used for infectious risk stratifi cation in 
the coming years. 
 However, many genetic association studies still need 
further validation, as their quality and methodological 
approaches are quite variable. Most common limitations 
include limited sample size in retrospective studies, use of 
inappropriate or ill-defi ned controls (no reporting or adjust-
ment for underlying diseases, type of transplant, degree 
and duration of immunosuppression, antifungal drugs or 
concomitant infections), absence of time-dependent analy-
ses, no reporting on ethnicity, lack of correction for mul-
tiple testing with respect to the multiplicity of markers, 
absence of replication studies to validate new associations 
and over-interpretation of negative results in underpowered 
studies. Furthermore, many studies have focused on one or 
a limited number of genetic markers, without accounting 
for the others. Due to the ethnic diversity, polymorphisms identifi ed as risk factors in a given population may not 
apply to another one [110]. 
 Larger studies with detailed clinical data will help to 
precisely determine the individual contribution of several 
individual polymorphisms to the risk of developing the 
disease. New approaches combining the use of well defi ned 
host genetic markers, more sensitive and specifi c serologic 
tests and improved radiological surveillance may signifi -
cantly improve the management of IA in the future. 
 Declaration of interest: The authors report no confl icts of 
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